本文關(guān)鍵詞： 炎癥性腸病 疾病管理 服藥依從性 生活質(zhì)量 隨訪　出處：《中國(guó)全科醫(yī)學(xué)》2016年35期 　論文類型：期刊論文

【摘要】：目的探討對(duì)炎癥性腸病(IBD)患者實(shí)施以專病管理團(tuán)隊(duì)為主導(dǎo)的疾病管理的效果。方法采用便利抽樣法,選取2014年3月—2015年2月在南京中醫(yī)藥大學(xué)附屬醫(yī)院脾胃病科就診的IBD患者131例,采用隨機(jī)數(shù)字表法將其分為對(duì)照組(65例)和干預(yù)組(66例),對(duì)照組給予常規(guī)專病門診隨訪和健康教育,干預(yù)組實(shí)施以專病管理團(tuán)隊(duì)為主導(dǎo)的疾病管理和隨訪。采用Morisky用藥依從性量表(MMAS)、IBD患者生活質(zhì)量問卷(IBDQ)、醫(yī)院焦慮抑郁量表(HADS)、IBD癥狀體征分級(jí)量化評(píng)分表分別評(píng)價(jià)患者干預(yù)前、干預(yù)第3個(gè)月、干預(yù)第6個(gè)月時(shí)用藥依從性、生活質(zhì)量評(píng)分、焦慮抑郁狀況以及癥狀嚴(yán)重程度。結(jié)果干預(yù)方法、時(shí)間對(duì)患者M(jìn)MAS評(píng)分主效應(yīng)顯著(P0.05);干預(yù)第3、6個(gè)月,干預(yù)組MMAS評(píng)分高于對(duì)照組(t=6.530,P0.001;t=3.813,P=0.006)。干預(yù)方法、時(shí)間對(duì)患者腸道癥狀、全身癥狀、社會(huì)功能評(píng)分以及IBDQ總分主效應(yīng)顯著(P0.05)。干預(yù)第3、6個(gè)月時(shí),干預(yù)組焦慮、抑郁狀況均優(yōu)于對(duì)照組(P0.05)。干預(yù)方法、時(shí)間對(duì)患者IBD癥狀體征分級(jí)量化評(píng)分主效應(yīng)顯著(P0.05);干預(yù)第3、6個(gè)月,干預(yù)組IBD癥狀體征分級(jí)量化評(píng)分低于對(duì)照組(t=2.114,P=0.035;t=2.239,P=0.020)。結(jié)論以專病管理團(tuán)隊(duì)為主導(dǎo)的疾病管理能夠有效提高IBD患者用藥依從性,提高生活質(zhì)量,降低焦慮、抑郁水平,改善疾病癥狀。
[Abstract]:Objective to investigate the effect of disease management in IBD patients with inflammatory bowel disease (IBD). From March 2014 to February 2015, 131 patients with IBD were selected from the Department of spleen and stomach Diseases, affiliated Hospital of Nanjing University of traditional Chinese Medicine. It was divided into control group (n = 65) and intervention group (n = 66) by random digital table. The control group was followed up and given health education. The intervention group carried out disease management and follow-up led by the special disease management team. The Morisky compliance scale was used to evaluate the patients' quality of life (QOL), and the hospital anxiety and depression scale (HADS) was used to evaluate the patients before intervention. At the 3rd month, the sixth month, the drug compliance, quality of life score, anxiety and depression status, and the severity of symptoms. Results the main effect of the intervention method on the MMAS score of the patients was significant (P 0.05), and at the 3rd and 6th month, the main effect of intervention was significant (P < 0.05). The MMAS score in the intervention group was higher than that in the control group (6.530g / 0.001). The intervention method was significant for the patients' intestinal symptoms, systemic symptoms, social function scores and total IBDQ scores (P 0.05). At the 3rd and 6th month after intervention, anxiety was observed in the intervention group. The depression status was better than that in the control group (P 0.05). The main effect of intervention method and time on the grading and quantification of IBD symptoms and signs was significant (P 0.05), and the intervention was at the 3rd and 6th month. The scores of IBD symptoms and signs in the intervention group were lower than those in the control group. Conclusion the disease management led by the special disease management team can effectively improve the compliance of drug use, improve the quality of life, reduce anxiety and depression, and improve the symptoms of IBD.
【作者單位】： 南京中醫(yī)藥大學(xué)附屬醫(yī)院脾胃病科;南京中醫(yī)藥大學(xué)附屬醫(yī)院護(hù)理部;
【基金】：南京中醫(yī)藥大學(xué)附屬醫(yī)院/江蘇省中醫(yī)院院級(jí)課題(Y14039)
【分類號(hào)】：R574
，

本文編號(hào)：1506152